...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hepatology research: the official journal of the Japan Society of Hepatology >Omics-derived hepatocellular carcinoma risk biomarkers for precision care of chronic liver diseases
【24h】

Omics-derived hepatocellular carcinoma risk biomarkers for precision care of chronic liver diseases

机译：Omics-derived肝细胞癌的风险生物标志物精密照顾慢性肝脏疾病

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Precise hepatocellular carcinoma (HCC) risk prediction will play increasingly important roles with the contemporary HCC etiologies, that is, non-alcoholic fatty liver disease and resolved hepatitis C virus infection. Because the HCC incidence rate in this emerging patient population is relatively low (1% per year), identification of a subset of patients at the highest risk is critical to concentrate the effort and resources of regular HCC screening to those who most need it. Omics profiling has been derived using several candidate HCC risk biomarkers, which could refine HCC screening by enabling individual risk-based personalized or risk-stratified patient management. Various types of biomolecules have been explored as sources of information to predict HCC risk at various time horizons. Germline DNA polymorphisms likely reflect race/ethnicity- and/or etiology-specific susceptibility to HCC development or chronic liver disease progression toward carcinogenesis. Transcriptomic dysregulations in the diseased liver capture functional molecular status supporting oncogenesis such as inflammatory pathway and myofibroblast activation. Circulating nucleic acids, proteins, and metabolites could serve as less-invasive measures of molecular HCC risk. Characterization of gut microbiota could also inform HCC risk estimation. Each biomarker could have its niche of clinical application depending on logistics of use, performance, and costs with a goal to eventually improve patient prognosis as a part of the whole algorithm of chronic liver disease management.
机译：精确的肝细胞癌(HCC)的风险预测将会扮演越来越重要的角色与当代肝癌病因,非酒精脂肪肝疾病和解决丙型肝炎病毒感染。发病率在这个新兴的病人每年人口相对较低(1%),识别病人的一个子集最高风险集中至关重要努力和资源定期HCC筛查那些最需要它的人。导出使用几个候选人肝癌的风险生物标志物,提炼HCC筛查个人风险个性化或启用risk-stratified病人管理。生物分子的探索的来源信息预测肝癌风险在不同的时间的视野。反映了种族和/或etiology-specific对肝癌发展或慢性肝脏疾病进展向致癌作用。转录组的失调肝脏捕获功能分子状态支持炎症等肿瘤形成途径和myofibroblast激活。核酸、蛋白质和代谢物作为侵害分子HCC的措施风险。也通知肝癌风险评估。可能的利基临床应用根据物流的使用、性能和成本与最终目标是改善病人预后的整个算法的一部分慢性肝病的管理。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号